Pretreatment characteristics
| Characteristics n = 300 unless stated . | n (%) unless stated . |
|---|---|
| Age, median (y) (range, y) | 57 (17-86) |
| Age ≥65 | 72 (24) |
| B2M ≥4.0 mg/L, n = 296 | 128/296 (43) |
| Binet stage | |
| A | 76 (25) |
| B | 145 (48) |
| C | 78 (26) |
| Rai stage III-IV | 107 (36) |
| Male gender | 211 (70) |
| ECOG PS | |
| 0 | 119 (40) |
| 1 | 171 (57) |
| 2 | 10 (3) |
| IGHV unmutated, n = 214 | 126 (59) |
| WCC ≥200 × 109/L | 27 (9) |
| LDH > ULN | 108 (36) |
| ZAP70 positive by IHC, n = 209 | 126 (60) |
| Del(17p) by karyotyping, n = 222 | 5 (2) |
| Characteristics n = 300 unless stated . | n (%) unless stated . |
|---|---|
| Age, median (y) (range, y) | 57 (17-86) |
| Age ≥65 | 72 (24) |
| B2M ≥4.0 mg/L, n = 296 | 128/296 (43) |
| Binet stage | |
| A | 76 (25) |
| B | 145 (48) |
| C | 78 (26) |
| Rai stage III-IV | 107 (36) |
| Male gender | 211 (70) |
| ECOG PS | |
| 0 | 119 (40) |
| 1 | 171 (57) |
| 2 | 10 (3) |
| IGHV unmutated, n = 214 | 126 (59) |
| WCC ≥200 × 109/L | 27 (9) |
| LDH > ULN | 108 (36) |
| ZAP70 positive by IHC, n = 209 | 126 (60) |
| Del(17p) by karyotyping, n = 222 | 5 (2) |
ECOG, Eastern Co-operative Oncology Group; PS, performance status; WCC, white cell count.